Capitolul 10 - BIBLIOGRAFIE - Ghid din 2019 privind boala tromboembolică în sarcină şi lehuzie

M.Of. 738 bis

În vigoare

Versiune de la: 10 Septembrie 2019

CAPITOLUL 10:BIBLIOGRAFIE

(1)Screening. Grupe de risc

1.James AH et al. Venous thromboembolism during pregnancy and the postpartum period: Incidence, risk factors and mortality. Am J Obstet Gynecol 2006; 194:1311.

2.Heit JA et al. Trends in the Incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143:697.

3.Stein PD et al. Venous thromboembolism in pregnancy: 21-year trends. Am J Med 2004; 117:121.

4.Drife J, Lewis G (eds.). Why mothers die 1997 - 1999. Confidential enquiries into maternal deaths in the United Kingdom. UK RCOG Press, London, 2001.

5.Greer IA. Epidemiology, risk factors and prophylaxis of venous thrombo-embolism In obstetrics and gynecology. Baillieres Clin Obstet Gynecol 1997; 11:403-430.

6.Friederich, PW, Sanson, B-J, Simionl, P, et al.Frequency of pregnancy related venous thromboembolism: in anticoagulant factor deficient women: Implications for prophylaxis. Ann Intern Med 1996; 125:955.

7.McColl, MD, Ramsay, JE, Tait, RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78:1183.

8.Grandone, E, Margaglione, M, Colaizzo, D, et al. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20120A, and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol 1998; 179:1324.

9.Nicolaides AN et al. Prevention and treatment of venous thromboembolism. International Consensus Statement. Guidelines according to scientific evidence. Int Angiol 2006; 25:101-61.

10.RCOG (Royal College of Obstetricians and Gynecologysts). Thromboprophylaxis during pregnancy, labor and after vaginal delivery. RCOG Guideline No. 37, January 2004.

11.Bates SM, Greer IA et al. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Use of antithrombotic agents during pregnancy. Chest 2004; 126:627S.

12.Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143:697.

13.Sultan AA, Tata LJ, West J, et al. Risk factors for first venous thromboembolism around pregnancy: a population-based cohort study from the United Kingdom. Blood 2013; 121:3953.

14.Sultan AA, West J, Tata LJ, et al. Risk of first venous thromboembolism in pregnant women in hospital: population based cohort study from England. BMJ 2013; 347:f6099.

15.Sultan AA, West J, Grainge MJ, et al. Development and validation of risk prediction model for venous thromboembolism in postpartum women: multinational cohort study. BMJ 2016; 355:i6253.

16.Robertson L, Wu O, Langhorne S et al. Thrombophilia in pregnancy: A systematic review. Br J H aematol 2006; 132:171-96.

17.Miyakis S, Lockshin MD, Atsumi T et al.International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome ( APS). JThromb Haemost 2006; 4(2):295-306.

18.American College of Obstetricians and Gynecologysts. Antifosfolipidic syndrome.AGOG Practice Buletin Nr.132.ObstetGynecol, 120, 6, 1514-21, 2012.

19.Virkus, RA, Lokkegaard EC, Bergholt T, Mogensen U, Langhoff- Ross J, Lidegaard O. Venous thromboembolism in pregnant and puerperal women in Denmark 1995-2005. A national cohort study. Thromb Haemost 2011; 106(2): 204-309. [II-2]

20.Royal College of Obstetricians and Gynaecologists (RCOG): Green-top guideline on reducing the risk of venous thromboembolism during pregnancy and the puerperium, 3rd edition, 2015.

21.Berghella V.Maternal-Fetal Evidence Based Guidelines Third Edition. 2017; 254-283.

(2)Diagnosticul bolii tromboembolice

1.RCOG (Royal College of Obstetricians and Gynecologysts). Thromboembolic disease in pregnancy and the puerperlum: acute management. RCOG Guideline No. 28, July 2006.

2.Nicolaides AN. Thrombophilia and venous thromboembolism. International Consensus Statement. Guidelines according to scientific evidence. Int Angiol 2005; 24:1-26.

3.Dizon-Townson D, Sibai B et al. The relationship of factor V Leiden mutation and pregnancy outcome for mother and fetus. Obstet Gynecol 2005; 106:517.

4.Gibson CS et al. Associations between fetal Inherited thrombophilia and adverse pregnancy outcomes. Am J Obstet Gynecol 2006; 194:947.

5.Robertson L et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132:171.

6.Lockwood, CJ. Heritable coagulopathies in pregnancy. Obstet Gynecol Surv 1999; 54:754.

7.Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. N Engl J Med 2008; 359:2025.

SECŢIUNEA 2:Conduită

1.Pregnancy: Venous Thromboembolism Treatment, Thrombosis Canada 2017.

2.Gates S et al. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev 2002; :CD001689.

3.Nicolaides AN et al. Prevention and treatment of venous thromboembolism. International Consensus Statement. Guidelines according to scientific evidence. Int Angiol 2006; 25:101-61.

4.Hirsh J, Guyatt G et al. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Evidence-Based Guidelines. Chest 2004; 126:172S-173.

5.Schunemann H, Munger H et al. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Methodology for guideline development for the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:174S-178.

6.Guyatt G, Schunemann H et al. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Applying the grades of recommendation for antithrombotic and thrombolytic therapy. Chest 2004; 126:179S-187.

7.Bates SM, Greer IA et al. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Use of antithrombotic agents during pregnancy. Chest 2004; 126:627S.

8.RCOG (Royal College of Obstetricians and Gynecologysts). Thromboprophylaxis during pregnancy, labor and after vaginal delivery. RCOG Guideline No. 37, January 2004.

9.RCOG (Royal College of Obstetricians and Gynecologysts). Thromboembolic disease in pregnancy and the puerperium: acute management. RCOG Guideline No. 28, July 2006.

10.SIGN (Scottish Intercollegiate Guidelines Network). Prophylaxis of venous thromboembolism: a national clinical guideline. SIGN Publication No. 62, October 2002.

11.ACOG (American College of Obstetricians and Gynecologysts). Thromboembolism in pregnancy. ACOG practice bulletin 19, 2000.

12.Inherited thrombophilias in pregnancy. Practice Bulletin No.138 American College of Obstetricians and Gynecologists. Obstet Gynecol 2013:122:706-17.

13.Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism In pregnancy: a systematic review of safety and efficacy. Blood 2005; 106:401.

14.Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107:19.

15.Kearon C. Epidemiology of venous thromboembolism. Semin Vase Med 2001; 1:7-26.

16.Goldhaber SZ, Grodstein F et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997; 277:642-5.

17.Greer IA. Epidemiology, risk factors and prophylaxis of venous thrombo-embolism in obstetrics and gynecology. Baillieres Clin Obstet Gynecol 1997; 11:403-430.

18.Bain E, Wilson A, Tooher R, Gates S, Davis LJ, Middleton P. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period (Review)Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD001689.

19.American College of Obstetricians and Gynecologists. Antiphospholipid syndrome. ACOG Practice Bulletin No. 132. Obstet Gynecol 2012; 120(6): 1514-21. [Review].

20.Gris JC, Bouvier S, Molinari N, Galanaud JP, Cochery-Nouvellon E, Mercier E, Fabbro-Peray P, Balducchi JP, Mares P, Quere I, Dauzat M. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: The NOH-APS observational study. Blood 2012; 119(11): 2624-32. [Case control, n = 1592].

21.Pattison NS, Chamley LW, Birdsall M et al. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol 2000; 183: 1008-12. [RCT, n = 50].

22.Cowchock S, Reece EA. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Am J Obstet Gynecol 1997; 176: 1099-100. [RCT, n = 19].

23.Tulppala M, Marttunen M, Soderstrom-Anttila V et al. Low-dose aspirin prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: Effect on prostacyclin and thromboxane A2 production. Hum Reprod 1997; 12: 1567-72. [RCT, n = 66].

24.Empson M, Lassere M, Craig JC et al. Recurrent pregnancy loss with antiphospholipid antibody: A systematic review of therapeutic trials. Obstet Gynecol 2002; 99: 135-44. [Meta-analysis; 10 RCTs; includes Refs. 2, 3, 4, 6, 8, 9, 10, 11, 12; n = 627].

25.Rai R, Cohen H, Dave M et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipids antibodies. BMJ 1997; 314: 253-7. [RCT, n = 90].

26.Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584-9. [RCT, n = 50].

27.GoelN, TuliA, ChoudhryR. The role of aspirin versus aspirin and heparin in cases of recurrent abortions with raised anti-cardiolipin antibodies. Med Sci Monit 2006; 12: CR132-6. [RCT, n = 72].

28.FarquharsonRG, QuenbyS, GreavesM. Antiphospholipidsyn - drome in pregnancy: A randomized controlled trial of treatment. Lupus 2002; 100: 408-13. [RCT, n = 98].

29.Laskin CA, Spitzer KA, Clark CA et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: Results from the randomized, controlled HepASA trial. J Rheumatol 2009; 36: 279-87. [RCT, n = 88].

30.Ziakas P, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss. Obstet Gynecol 2010; 115: 1256-62. [Review].

31.Noble LS, Kutteh WH, Lashey N et al. Antiphospholipid anti-bodies associated with recurrent pregnancy loss: Prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril 2005; 83: 684-90. [RCT, n = 50].

32.StephensonMD, BallemPJ, TsangPetal.Treatmentofantiphos-pholipid antibody syndrome (APS) in pregnancy: A randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can 2004; 26: 729-34. [RCT, n = 26].

33.Fouda UM, Sayed AM, Abdou AM, Ramadan DI, Fouda IM, Zaki MM. Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospho- lipid syndrome. Int J Gynaecol Obstet 2011; 112(3): 211-5. BMID 21251653. [RCT, n = 60]

34.Mak A, Cheung MW, Cheak AA, Ho RC. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: A meta-analysis of randomized controlled trials and meta-regression. Rheumatology 2010; 49(2): 281-8. [Meta-analysis, 334 women in 5 studies - references 5, 8, 9, 11, 12]

35.Silver RK, MacGregor SN, Sholl JS et al. Comparative trial of prednisone plus aspirin vs. aspirin alone in the treatment of anticardiolipin antibody positive obstetric patients. Am J Obstet Gynecol 1993; 169: 1411-7. [RCT, n = 39].

36.Laskin CA, Bombardier C, Hannah ME et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997; 337: 148-53. [RCT, n = 202].

37.Branch DW, Peaceman AM, Druzin M et al. A multicenter placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol 2000; 182: 122-7. [RCT, n = 16].

38.El-Haieg AU, Zanati MF, El-Foual FM. Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome. Int J Gynaecol Obstet 2007; 99(3): 236. [Case series, n=18].

39.Berghella V.Maternal-Fetal Evidence Based Guidelines Third Edition. 2017; 254-283.

40.American College of Obstetricians and Gynecologists Practice Bulletin Number 138, September 2013. Obstet Gynecol, 122, 706-17, 2013.

41.Rolnik DL, Wright D, Poon LCY, Syngelaki A, O'Gorman N, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Nicolaides KH. ASPRE trial: performance of screening for preterm pre-eclampsia.Ultrasound Obstet Gynecol. 2017 Oct; 50(4):492-495.

SECŢIUNEA 3:Urmărire şi monitorizare

1.Bates, SM, Ginsberg JS. How we manage venous thromboembolism during pregnancy. Blood 2002; 100:3470.

2.Thromboembolism In pregnancy, ACOG practice bulletin #19. American College of Obstetricians and Gynecologists, Washington, DC, 2000.

3.Bates SM, et al. Guidance for the treatment and preventionn of obstetric-associated venous thromboembolism. J Thromb Thrombolysis 2016; 41(1):92-128.